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ABSTRACT
Background: Chronic hepatitis C virus (HCV) infection causes intra- and extra-hepatic complications. The
elimination of HCV has been reported to be beneficial for asthmatic patients with HCV infection. Therefore, we
hypothesized that chronic HCV infection might be associated with the severity of asthma.
Methods: Asthmatic patients were prospectively enrolled from 13 outpatient settings. Hepatitis B surface
(HBs) antigen and HCV-RNA were measured at the time of enrollment and evaluated along with the clinical
characteristics of the patients including the age, sex, duration of asthma, atopic status, smoking history, and
treatment step according to the Global Initiative for Asthma guideline.
Results: Of 1327 asthmatic patients, 1258 patients (94.8%) were treated with inhaled corticosteroids, 18 pa-
tients were positive for HBs antigen (1.4%), and 32 patients (2.4%) were positive for HCV-RNA. When com-
pared with HCV-RNA-negative patients, HCV-RNA-positive patients required significantly more drugs for the
treatment of asthma. No such relationship was observed in patients with positive HBs antigen. A multivariate lo-
gistic regression analysis showed that the male sex, a long duration of asthma, status as a current smoker, and
HCV-RNA positivity were independently associated with more severe asthma.
Conclusions: These results suggest that chronic HCV infection is an independent factor that predisposes
asthmatic patients to more severe asthma. The evaluation of chronic HCV infection may be helpful for the man-
agement of severe asthmatic patients without obvious factors associated with severe asthma.
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INTRODUCTION
Since the presence of eosinophilic airway inflamma-
tion is recognized as a consistent feature of naïve
asthma, there is no doubt that inhaled corticosteroids
play a central role in the treatment of asthma.1 In-
haled corticosteroids have drastically improved both
the symptoms and the prognosis for this chronic in-
flammatory disease.1-3 Most persistently asthmatic
patients are well or totally controlled with inhaled cor-
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ticosteroids alone, but there are some who need
more drugs in addition to inhaled corticosteroid.4,5
Such a population, presenting persistent symptoms
despite add-on therapy with a class of controllers
other than inhaled corticosteroids, is defined as hav-
ing severe asthma.6 Although the underlying factors
that predispose asthmatic patients to severe asthma
are not yet fully understood, multiple factors includ-
ing tobacco smoking,7 genetic factors,8 a predomi-
nance of neutrophilic inflammation in the airway,9 in-
creased tissue injury and remodeling,10 a molecular
background including reduced histone deacetylase-2
expression,8 chronic stress,11 and poor adherence12
are supposed to be involved in this unfavorable phe-
notype.
Chronic infection with hepatitis C virus (HCV) is
believed to cause intra- and extra-hepatic complica-
tions. Among the extra-hepatic complications, the
lung is one major target organ.13 HCV infection re-
sulted in a worsening of lung function, interstitial
pneumonitis and pulmonary fibrosis in some patients.
In patients with preexisting asthma, HCV infection is
associated with an accelerated decline in lung func-
tion.14 Successful treatment in the elimination of HCV
with interferon-gamma is associated with a preven-
tion of declining lung function in patients with persis-
tent asthma complicated with chronic HCV infec-
tion.14,15 These results suggest that infection with
HCV may affect the severity of asthma and, thereby,
the treatment of asthma.
From this point of view, we hypothesized that
chronic HCV infection might be involved in the sever-
ity of asthma. To test this hypothesis, we evaluated
the relationship between chronic HCV infection in
asthmatic patients and the Global Initiative for
Asthma (GINA) treatment step, which is associated
with the severity of asthma.1
METHODS
SUBJECTS AND DESIGN
The protocol of this multicenter, cross-sectional study
was approved by the institutional review board of
Hiroshima University (Ethical Review Board for Clini-
cal Study of Hiroshima University, approved number
247), and Ehime University (Ethical Review Board for
Clinical Study of Ehime University Hospital, approved
number 16-54). All patients gave informed consent
before any study-related procedures were performed.
We prospectively recruited all chest physician-
diagnosed asthmatic patients who visited 13 outpa-
tient settings in Japan (Hiroshima University-related
hospitals and clinics: Hiroshima University Hospital,
Chugoku Rousai Hospital, Hiroshima Allergy and
Respiratory Clinic, Hiroshima City Funairi Hospital,
Hiroshima General Hospital of West Japan Railway
Company, Hiroshima Prefectural Hospital, Ikuta
Medical Clinic, JA Hiroshima General Hospital, Taka-
hashi Medical Clinic and Tsuya Clinic; Ehime
University-related hospitals: Ehime University Hospi-
tal, Ehime Prefectural Imabari Hospital, and Uwajima
City Hospital) between October 18, 2004, and Decem-
ber 12, 2004. The diagnosis of asthma was made by
specialized pulmonologists according to typical asth-
matic symptoms including wheezing, coughing, dysp-
nea, and chest tightness that are often more problem-
atic at night.
Eligible patients were typical asthmatic patients
who had been treated in an outpatient setting for at
least 6 months. During the recruitment period, we in-
cluded the asthmatic patients regardless of the past-
medical history of HCV treatment. We excluded pa-
tients who were judged as having poor adherence to
the medication, who presented obvious malignancy,
or who had obvious other respiratory diseases or
other systemic diseases requiring oral corticosteroids
(i.e., Churg-Strauss syndrome, allergic bronchopul-
monary aspergillosis). The clinical characteristics of
the patients, including age, sex, duration of asthma,
atopic disposition, smoking history, and medical
treatment for asthma, were recorded at the time of
enrollment. Based on the GINA guidelines,1 atopic
asthmatic patients are defined as those who pre-
sented positive skin-prick tests or higher levels of se-
rum IgE specific to common environmental allergens
compared to the normal range. Current smokers
were defined as those having a smoking status with a
greater than a 10 pack-year smoking history.16 Based
on Japanese guideline produced by Japanese Society
of Allergology, we defined the “more severe asthma
patients” as patients who required step 4 treatment in
Japanese Society of Allergology guideline, because
the treatment step 4 in Japanese guideline is the most
severe group. When we applied our definition into
GINA guideline, treatment step 4 in Japanese guide-
line were equivalent of treatment step 4-5 in GINA
guideline. Therefore, we defined “more severe
asthma patients” as patients who required step 4-5
treatment in GINA guideline. Thus, we compared pa-
tients who required GINA treatment at steps 1-3 or
steps 4-5 to control asthmatic symptoms. In the HCV-
RNA positive asthmatics treated with GINA 4-5 treat-
ment steps, the lung function data performed within 3
months during the registration period were also col-
lected.
HEPATITIS VIRAL INFECTION
Following enrollment, the patients who participated
in the study were evaluated for hepatitis B surface
(HBs) antigen and anti-HCV antibody. Most patients
had not been examined for HCV infection. HBs anti-
gen was measured with a chemiluminescent enzyme
immunoassay (Lumipulse II HBsAg, Fujirebio Inc.,
Tokyo, Japan). Anti-HCV antibody was measured
with a third-generation chemiluminescent enzyme
immunoassay (Lumipulse II Ortho HCV, Ortho Clini-
cal Diagnostics, Tokyo, Japan). HCV-RNA was fur-
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Table　1　Characteristics of asthmatic patients at enrollment
Characteristics Asthmatic patients(n = 1327)
Median age-yrs (range) 57.8 (15-94)
Female sex-no. (%) 815 (61.4)
Duration of asthma-yrs (range) 8.3 (1.0-71.0)
Atopic predisposition-no. (%) 693 (52.2)
Never/Ex/Current smoker-no. (%) 932 (70.2)/229 (17.2)/
166 (12.5)
GINA treatment steps-no. (%)
Step 1 69 (5.2)
Step 2 335 (25.2)
Step 3 443 (33.4)
Step 4 408 (30.7)
Step 5 72 (5.4)
Hepatitis virus
HCV antibody positivity-no. (%) 67 (5.0)
HCV-RNA positivity-no. (%) 32 (2.4)
HBs antigen positivity-no. (%) 18 (1.4)
GINA, Global Initiative for Asthma; HCV, hepatitis C virus; HBs, 
hepatitis B surface.
ther measured using reverse transcription-PCR (Am-
pliCap GT HCV MONITOR Test version 2.0, Roche
Diagnostics, Tokyo, Japan) in patients whose HCV
antibody levels were higher than the normal range.
STATISTICAL ANALYSIS
Results are shown as median values and ranges.
Groups were compared using the Mann-Whitney U-
test for median values and the Fisher’s exact test or
Chi-squared test for categorical data. Factors associ-
ated with more severe asthma (patients who required
GINA treatment at steps 4-5 to control asthmatic
symptoms) were evaluated using a logistic regression
model. Variables with statistically significant results
in the univariate analysis were included in a multivari-
ate analysis. Differences were considered statistically
significant when p-values were < 0.05. All analyses
were performed using SPSS for Windows, version
12.0 (SPSS Inc, Chicago, IL, USA).
RESULTS
During the 8 week recruitment period, 1790 consecu-
tive asthmatic patients were evaluated for enrollment.
Two hundred eighty-five patients declined to partici-
pate, and 178 patients did not meet the enrollment
criteria. Overall, 1327 asthmatic patients met the in-
clusion criteria and agreed to participate in the cur-
rent study. The characteristics of 1327 asthmatic pa-
tients from 12 outpatient settings are shown in Table
1. Of the 1327 asthmatic patients, 1258 patients
(94.8%) were treated with inhaled corticosteroids. Ad-
ditionally, among these 1327 patients, there were 18
patients positive for HBs antigen (1.4%) and 67 pa-
tients positive for HCV antibody (5.0%). Among the
67 asthmatic patients who were HCV antibody-
positive, 32 patients (2.4%) were also HCV-RNA-
positive (Table 1). There were no subjects who had
received interferon therapy, except for 1 patient, who
showed both positive for HCV antibody and negative
for HCV-RNA. Among 815 female subjects, 70 (8.6%)
were current smokers, whereas 96 of 512 (18.8%)
were current smokers among the male subjects (P <
0.001 by Fisher’s exact test).
The frequencies of HBs antigen-positive and HCV
antibody-positive patients were not different from the
reported frequencies among more than a million peo-
ple from the general population (i.e., blood donors) in
Japan,17 when age was matched for comparison (data
not shown).
When compared with HCV-RNA-negative patients,
HCV-RNA-positive patients required significantly
more drugs for the treatment of asthma (Fig. 1). No
such relationship was observed in patients with HCV
antibody or HBs antigen positivity. To identify the
factors associated with more severe asthma (patients
who required GINA treatment at steps 4-5 to control
asthmatic symptoms), logistic multiple regression
analysis was performed. The univariate analysis
showed that male sex, a long duration of asthma, cur-
rent smoker status, and HCV-RNA positivity were sig-
nificantly associated with more severe asthma,
whereas age, atopic disposition, outpatient settings
(in general hospital or clinic), HCV antibody positiv-
ity, and HBs antigen positivity were not (Table 2).
The multivariate analysis showed that male sex, a
long duration of asthma, current smoker status, and
HCV-RNA positivity were significantly and independ-
ently associated with more severe asthma (Table 2).
To clarify the characteristics of HCV-RNA positive
patients who required GINA treatment at steps 4-5 to
control asthmatic symptoms, we summarized the
data obtained from this group in Table 3. Among 20
HCV-RNA positive patients treated with GINA treat-
ment at steps 4-5, lung function data were available
from 12 patients (data of 5 patients were not available,
and 3 could not perform lung function test accu-
rately). As a result, airflow obstruction was observed
in this category of patients in spite of more aggres-
sive step 4-5 treatments.
DISCUSSION
This study suggested that the existence in the blood-
stream of HCV-RNA, but not of anti-HCV antibody or
HBs antigen, is associated with the severity of
asthma. Univariate and multivariate analyses also
demonstrated that chronic HCV infection is a signifi-
cant and independent factor predisposing asthmatic
patients to more severe asthma. Therefore, chronic
HCV, but not HBV infection, was considered an im-
portant factor for predisposing asthmatic patients to
more severe asthma. In addition, we also found that
both HBs antigen and HCV antibody positivity rates
Nakashima T et al.
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Fig.　1　Association between medical treatment steps defi ned by Global Initiative for Asth-
ma and chronic infection with hepatitis C virus (HCV) or hepatitis B virus. Asthmatic pa-
tients complicated with HCV infection required more add-on therapy with a class of con-
trollers other than inhaled corticosteroids than did patients without HCV infection. Hepatitis 
B viral infection showed no effect on the treatment of asthma.
GINA treatment step
1
HCV-RNA (+)
n = 32
HCV-RNA (-)
n = 1295
HBs antigen (+)
n = 18
HBs antigen (-)
n = 1309
2 3 4 5
P = 0.033
P = 0.393
P = 0.003
P = 0.321
 0 (0%)
 69 (5%)
 1 (6%)
 68 (5%)
 3 (9%)
 69 (5%)
 2 (11%)
 70 (5%)
 5 (16%)
 330 (26%)
 5 (28%)
 330 (25%)
 7 (22%)
 436 (34%)
 8 (44%)
 435 (33%)
 17 (53%)
 391 (30%)
 2 (11%)
 406 (31%)
 12 (38%)
 835 (64%)
 14 (78%)
 833 (64%)
 20 (63%)
 460 (36%)
 4 (22%)
 476 (36%)
Table　2　Factors associated with more severe asthma
95% confi dence interval
Variables Oddsratio Lower Upper P-value
Univariate analysis
Age (≥65 yrs) 1.010 0.798 1.278 0.933
Sex (male) 1.482 1.179 1.863 0.001
Duration (≥8 yrs) 1.289 1.028 1.615 0.028
Atopic predisposition (+) 0.893 0.714 1.117 0.321
Smoking (current smoker) 1.770 1.275 2.456 0.001
Outpatients settings (clinic) 1.113 0.884 1.402 0.362
HCV antibody (+) 1.283 0.779 2.114 0.327
HCV-RNA (+) 3.025 1.466 6.245 0.003
HBs antigen (+) 0.500 0.164 1.528 0.224
Multivariate analysis
Sex (male) 1.422 1.126 1.795 0.003
Duration (≥8 yrs) 1.319 1.049 1.658 0.018
Smoking (current smoker) 1.679 1.201 2.346 0.002
HCV-RNA (+) 2.997 1.443 6.223 0.003
Logistic multiple regression analysis was performed to identify
the factors associated with more severe asthma (patients who re-
quired GINA treatment at steps 4-5 to control asthmatic symp-
toms). HCV, hepatitis C virus; HBs, hepatitis B surface.
Table　3　Characteristics of severe asthmatic patients with 
chronic HCV infection
Characteristics
Median age-yrs (range), n = 20 65.0 (38-78)
Female sex-no. (%), n = 20 12 (60.0)
Duration of asthma-yrs (range),
n = 20
13.5 (1.0-50.0)
Atopic predisposition-no. (%),
n = 20
8 (40.0)
Never/Ex/Current smoker-no. 
(%), n = 20
11 (55.0)/4 (20.0)/5 (25.0)
Pack-years of smoking history 
(range), n = 9
30 (18-60)
GINA treatment steps-no. (%),
n = 20
Step 4 17 (85.0)
Step 5 3 (15.0)
FEV1-L (range), n = 12 1.76 (0.80-2.96)
Percent predicted FEV1-% 
(range), n = 12
67.8 (45.6-121.5)
FEV1/FVC-% (range), n = 12 68.1 (42.9-85.0)
Serum IgE-IU/mL (range), n = 15 180 (13-2200)
Peripheral blood eosinophils-/μL 
(range), n = 18
200 (0-1500)
GINA, Global Initiative for Asthma; HCV, hepatitis C virus.
in asthmatic patients were not significantly different
from those of the general population when adjusted
for age.17 These results suggest that chronic HCV in-
fection is related to the more severe phenotype in
asthma but is not a determinant of predisposition to
asthma.
We speculate that the underlying mechanism pre-
disposing asthmatic patients with chronic HCV infec-
tion to more severe asthma may be an alteration of
airway inflammation caused by HCV. Kanazawa et al.
reported that airway CD8+ T cells are increased in
asthmatic patients complicated with chronic HCV in-
fection when compared with asthmatic patients with-
out HCV infection.18 They also found that successful
treatment of HCV infection with interferon therapy in
asthmatic patients resulted in a reduction of CD8+ T
cells in the airway. On the other hand, Moorman et
Hepatitis C Virus and Severe Asthma
Allergology International Vol 60, No3, 2011 www.jsaweb.jp 303
al. discovered that HCV core protein directly induces
interleukin-8 expression and production from human
lung fibroblasts.19 Because interleukin-8 is a key in-
flammatory mediator that contributes to neutrophilic
inflammation and bronchoconstriction, they con-
cluded that a direct pro-inflammatory role of HCV
core protein may injure the airway in HCV-infected
patients. Our findings are consistent with these sug-
gested notions, and HCV may worsen the severity of
asthma via the alteration of airway inflammation. The
altered airway inflammation in HCV-RNA positive
asthmatics may result in remodeling of the airway
and airflow obstruction as shown in Table 3. In addi-
tion, it should be noted that the HCV-RNA positivity
rate in HCV antibody positive patients (47.8%) was
not high in the current study, suggesting half of pa-
tients had experienced a transient HCV infection.
Our results also demonstrated that a long duration
of asthma, male sex, and current smoker status were
independent factors involved in the severity of
asthma. A recent review suggested that a longer du-
ration of asthma is associated with more severe dis-
ease and irreversible airflow limitation, which was
thought to be caused by airway remodeling.10 The as-
sociation between a long duration of asthma and
more severe asthma observed in the current study is
consistent with this notion. Similarly, tobacco smok-
ing in asthmatic patients is regarded as an important
factor of severe asthma.7 In the current study, an as-
sociation between current smoker status and more
severe asthma was also observed. In addition, we
found that male sex is associated with more severe
asthma, a finding that may not be consistent with pre-
vious notions. Though there are several controversial
reports, severe asthma seems to be more common in
women than in men.4,5
There are several limitations in the current study.
First, detailed information regarding asthma control
and lung function was not available. However, we be-
lieve that the GINA treatment step evaluation re-
flected the severity of disease in this large scale popu-
lation. Second, the diagnosis of asthma was
physician-based. All of the physicians who partici-
pated in the current study were pulmonologists, help-
ing to explain the extremely high adoption rate of in-
haled corticosteroids (94.8%). Therefore, we believe
that the diagnosis is likely accurate. Finally, the ad-
herence of patients to the therapy was also physician-
evaluated. Though we excluded patients who were
judged as having poor adherence, the process may
not be sufficiently rigorous. Recently, Gamble et al.
tried to distinguish non-adherence to both inhaled
and oral corticosteroid therapy in asthmatic patients
by assessing prescription records and blood exams.12
Because non-adherence to medication is one of the
important factors that predisposes asthmatic patients
to false severe asthma, in future studies it will be nec-
essary to precisely evaluate the adherence to medica-
tion regimens in asthmatic patients complicated with
chronic HCV infection.12
In conclusion, this study demonstrated that
chronic HCV infection is one of the independent fac-
tors predisposing asthmatic patients to more severe
asthma. Although asthmatic patients complicated
with chronic HCV infection account for just a fraction
of asthmatic patients, we also conclude that the evalu-
ation of chronic HCV infection should be considered
to manage severe asthmatic patients without obvious
factors associated with severe asthma.
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